title: Does daily aspirin diminish severity of first-ever stroke?
abstract: BACKGROUND
  There are still uncertainties about aspirin efficacy in first-ever ischemic stroke prevention. Also it is unknown whether the severity of first ischemic stroke can be modified by aspirin pretreatment.
  
  
  OBJECTIVE
  To analyze a series of patients who had their first ischemic stroke while taking aspirin to evaluate the ability of aspirin prophylaxis to diminish the severity of first-ever ischemic stroke.
  
  
  METHODS
  Case-control study.
  
  
  METHODS
  Tertiary medical center to which patients were referred.
  
  
  METHODS
  All consecutive patients admitted to the Tel Aviv Medical Center, Tel Aviv, Israel, from May 1988 through May 1994 because of first-ever ischemic stroke were divided into 2 groups according to aspirin use before stroke: aspirin-treated and non-aspirin-treated groups.
  
  
  METHODS
  Stroke severity was defined according to activities of daily living within 24 hours after admission: (1) mild stroke, with independence in activities of daily living; (2) moderate stroke, with partial dependency; and (3) severe stroke, with complete dependency. Using chi 2 test, stroke severity was compared between patients taking aspirin before their stroke and non-aspirin-treated patients.
  
  
  RESULTS
  Among 2113 consecutive patients with first-ever ischemic stroke, 125 patients had already been taking 100 to 500 mg of aspirin daily. Aspirin-treated and non-aspirin-treated patients did not differ in stroke severity. Mortality was lower in aspirin-treated patients (7.9%) than in non-aspirin-treated patients (12%), but this difference was not statistically significant (P = 17).
  
  
  CONCLUSIONS
  We conclude that aspirin as primary prevention treatment has no significant protective effect on severity of first-ever ischemic stroke. The diminution of mortality after first ischemic stroke in patients who had used aspirin should be investigated further.
authors.affiliation: Department of Neurology, Tel Aviv Medical Center, Israel.
authors.forename: V
authors.initials: V
authors.lastname: Karepov
authors.forename: N M
authors.initials: NM
authors.lastname: Bornstein
authors.forename: Y
authors.initials: Y
authors.lastname: Hass
authors.forename: A D
authors.initials: AD
authors.lastname: Korczyn
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage*; D001241:Aspirin / Q000008:administration & dosage*; D002545:Brain Ischemia / Q000150:complications / Q000188:drug therapy; D016022:Case-Control Studies; D002561:Cerebrovascular Disorders / Q000188:drug therapy* / Q000209:etiology / Q000401:mortality; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D001241:Aspirin